Vaginal device aims to boost infection treatment

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female sex * Age 18 to 60 years * Able to understand and sign informed consent * Able to understand and comply with protocol requirements * Negative pregnancy test * Negative HIV test * Not taking, and agreeing not to take, any other medication or medical device for the duration of the study, except the elective antibacterial or antifungal treatment for BV or VVC * Presenting symptoms suggestive of BV or VVC at screening (leukorrhea, itching, burning) * Confirmed clinical diagnosis of bacterial vaginosis (yellow-green or gray vaginal discharge; vaginal pH \> 4.5; positive whiff test/fishy odor with potassium hydroxide), OR * Confirmed clinical diagnosis of vulvovaginal candidiasis (gynecological examination with itching, burning, thick white discharge; vaginal pH typically \< 4.5; vaginal swab confirmation of \*Candida\* spp.) Exclusion Criteria: * Male sex * Age \< 18 or \> 60 years * Pregnant, suspected pregnant, or planning pregnancy during the study period * Breastfeeding * Not self-sufficient * Unwilling/unable to cooperate with study procedures * Unable to attend the study site within the required timeframe * Judged unsuitable by the investigator due to other conditions incompatible with enrollment requiring pharmacological treatment * HIV-positive / acquired immunodeficiency * Known allergy to components of the investigational products (active or placebo) * Presence of vaginal infections other than BV or VVC * Alcohol, drug, nicotine, or excessive caffeine/theine abuse * Use of vaginal or systemic antifungal/antibiotic treatment within the 7 days prior to enrollment * Taking any other medication or medical device during the study period, except the elective treatment for BV/VVC\* * Systemic or immunosuppressive conditions interfering with symptom interpretation * Participation in another clinical study within the previous 30 days * If pharmacological treatment becomes necessary, this must be reported to the Principal Investigator, who will assess on a case-by-case basis whether the subject should be excluded.